Salivary Oxytocin as a Biomarker of Psychedelic Treatment

N/AEnrolling By InvitationNCT07345858

University of Geneva, Switzerland80 enrolled

Overview

This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Major Depressive Disorder (MDD)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>=18 years-old * MDD defined by DSM-V criteria, and resistant to treatment * Ongoing classical psychotherapeutic treatment * Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off). Exclusion Criteria: * Psychotic or bipolar disorder * High suicidal risk * Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders * Pregnancy or breastfeeding.

Locations (1)

Geneva University Hospitals

Geneva, Switzerland

Outcomes

Primary Outcomes

Salivary Oxytocin

Measure taken during psychedelic treatment

Time frame: One day

Secondary Outcomes

Beck Depression Inventory

Self-reported depressive symptoms

Time frame: 3 months

Cognitive Flexibility Inventory

Self-reported flexibility questionnaire

Time frame: 3 months

Trait anxiety inventory (STAI-T)

Self-reported anxiety symptoms

Time frame: 3 months

Cognitive Emotion Regulation Questionnaire (CERQ)

Self-reported cognitive emotion regulation strategies

Time frame: 3 months

Emotion Regulation Questionnaire

self-reported emotion regulation strategies

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.